Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Clin Cancer Res. 2019 Oct 25;26(3):738–745. doi: 10.1158/1078-0432.CCR-19-1402

Figure 3. Association between immune cell density and response to neoadjuvant trastuzumab plus lapatinib therapy.

Figure 3.

Box plots of density of individual immune cell subpopulations in the stromal (s-) and intratumoral (i-) areas (A), and box plots of percentage of s-TILs assessed by H&E (B) in patients achieving a pathological complete response (pCR, white) versus residual disease (non-pCR, grey). P-values were not adjusted for multiple comparisons.